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Disruption of COX-2 and eNOS does not confer protection from
cardiovascular failure in lipopolysaccharide-treated conscious
mice and isolated vascular rings. Am J Physiol Regul Integr Comp
Physiol 301: R412–R420, 2011. First published May 4, 2011;
doi:10.1152/ajpregu.00823.2010.—It was hypothesized that a serial
stimulation of vascular cyclooxygenase-2 (COX-2) with subsequent
activation of endothelial nitric oxide synthase (eNOS) is responsible
for decrease in blood pressure, cardiac performance, and vascular
reactivity in endotoxemia caused by LPS. The hypothesis was tested
in catheterized, conscious, freely moving, wild-type mice and mice
(C57BL/6J background) with targeted deletion of COX-2 and eNOS
that were given an intravenous LPS bolus (2 mg/kg, 055:B5). In vitro
studies were performed on murine aorta rings. LPS caused a concom-
itant decrease in mean arterial blood pressure (MAP) and heart rate
(HR) that was significant after 3 h and was sustained throughout the
experiment (8 h). The LPS-induced changes in MAP and HR were not
different from control in COX-2/ and eNOS/ mice. A prosta-
cyclin receptor antagonist (BR5064) blocked the hypotensive effect of
a prostacyclin agonist (beraprost), but did not attenuate the LPS-
induced decrease in MAP and HR. LPS decreased eNOS and neuronal
NOS mRNA abundances in several organs, while inducible NOS
mRNA was enhanced. In aortic rings, LPS suppressed 1-adrenocep-
tor-mediated vascular tone. Inhibition of COX-2 activity (NS 398),
disruption of COX-2, endothelium removal, or eNOS deletion
(eNOS/) did not improve vascular reactivity after LPS, while the
NO synthase blockers 1400W and NG-nitro-L-arginine methyl ester
prevented loss of tone. COX-2 and eNOS activities are not necessary
for LPS-induced decreases in blood pressure, heart rate, and vascular
reactivity. Inducible NOS activity appears crucial. COX-2 and eNOS
are not obvious therapeutic targets for cardiovascular rescue during
gram-negative endotoxemic shock.
iNOS; prostacyclin; nitric oxide; endothelium
GRAM-NEGATIVE BACTERIAL ENDOTOXEMIA with sepsis is a sys-
temic response to infection that occurs with an increasing
incidence. The systemic inflammatory response may be com-
plicated by cardiovascular collapse with fatal blood pressure
decline and multiorgan failure (8). It remains a significant
challenge to define pharmacologic targets for intervention that
protect and improve cardiovascular performance. Cyclooxy-
genase-2 (COX-2) expression and activity is stimulated in
macrophages and endothelial cells by gram-negative bacterial
wall-derived LPS (1). The levels of the potent vasodilators
prostaglandin E2 (PGE2) and prostacyclin (PGI2) are increased
in patients with septic shock (6). The effect of COX inhibitors
on survival and cardiovascular parameters in septic shock is,
however, contradictory. In septic patients, ibuprofen reduced
urinary levels of metabolites of prostacyclin and thromboxane
A2 but not the incidence or duration of shock or the rate of
survival (7, 24). Ibuprofen rapidly reversed hypotension in
dogs exposed to endotoxin (2) and improved several vascular
parameters in pigs (21). Indomethacin improved survival but
had no significant effect on mean arterial blood pressure
(MAP) in dogs exposed to endotoxin (22), whereas in rats,
indomethacin did not reduce the mortality rate (3). In anesthe-
tized rats, the LPS-induced acute decrease in arterial blood
pressure was attenuated significantly by a selective COX-2
inhibitor (rofecoxib) and a nonselective COX inhibitor (indo-
methacin) (25). Mice with targeted deletion of COX-2 (19)
and mice treated with COX-2 inhibitors (34) exhibit im-
proved survival when challenged with LPS, but the cardio-
vascular effects of LPS have not previously been examined
in COX-2/ mice. Nitric oxide (NO) produced by inducible
NO synthase (iNOS) is of major importance for changes in
blood pressure during sepsis (23). Apparently, the activity of
endothelial NOS (eNOS) is required for the induction of iNOS,
and arterial blood pressure is protected in LPS-treated anes-
thetized eNOS/ mice (17, 38), although lethality is not
affected (35). PGE2 stimulates eNOS activity and PGE2-me-
diated vasodilatation depends on the presence of endothelium
and eNOS (27). A similar endothelium-dependency is seen
also for PGI2-induced vasodilatation (36). These findings
prompted the hypothesis that serial activation of COX-2 and
eNOS by LPS may account for the involvement of both
enzymes in the circulatory response to LPS. This hypothesis
predicts that functional deletion of COX-2 or eNOS protects
cardiovascular status equally well against LPS-induced cardio-
vascular depression through attenuated vasodilatation of resis-
tance vessels. The hypothesis was tested in vivo in mice with
targeted disruption of COX-2 and eNOS that were challenged
with Escherichia coli-derived LPS (055:B5). Arterial blood
pressure and heart rate were measured continuously in freely
moving mice with chronic indwelling catheters mounted in a
swivel system. To further address the involvement of the
vasculature, in vitro myograph experiments were performed
with isolated, LPS-treated, aortic rings prepared from wild-
type, COX-2/, or eNOS/ mice.
MATERIALS AND METHODS
Mice
The investigation conformed with the Guide for the Care and Use
of Laboratory Animal published by the US National Institutes of
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Health (NIH publication no. 85-23, revised 1996), and the experimen-
tal protocol was approved by the Danish Animal Experiments Inspec-
torate (no. 2009/561-1749) under the Danish Ministry of Justice. All
experiments in mice were performed in accordance with the Danish
national guidelines for care and handling of animals. C57BL/6J
wild-type mice and C57BL/6J mice with targeted deletion of COX-2
and eNOS were studied. COX-2/ mice and their wild-type litter-
mates (COX-2/) from heterozygos breeding were obtained from
Jackson Laboratories on a predominant C57BL/6 background and
further backcrossed for seven generations (C57BL/6) before experi-
ments. Genotyping was done with DNA from tail biopsies using the
REDExtract-NAmp tissue PCR kit (Sigma). PCR used the following
primers: (COX-2/) 5=-GCC-CTG-AAT-GAA-CTG-CAG-GAC-G-
3=, 5=-CAC-GGG-TAG-CCA-ACG-CTA-TGT-C-3=; (COX-2/)
5=-CAC-CAT-AGA-ATC-CAG-TCCGG-3= and 5=-ACC-TCT-GCG-
ATG-CTC-TTC-C-3=. In studies with eNOS/ mice (Jackson Lab-
oratories), C57BL/6J wild-type mice were used as controls. Mice
were 8–10 wk of age and were kept on a 12:12-h light-dark cycle with
free access to standard mice chow and tap water.
Blood Pressure Measurement
Mice were anesthetized (50 mg/kg ketamine and 10 mg/kg
xylazine ip) and catheters were placed in the femoral artery and vein
for blood pressure measurement and drug infusion, respectively (27).
Mice were then placed in individual cages, and catheters were at-
tached to a swivel (Instech Laboratories) so that the mice were able to
move freely. Mice recovered for 4 days after the operation, and in that
period the arterial catheters were kept open with infusion of 10 l/h
heparin solution (100 units in glucose). Before the experiment, the
artery line was connected to a pressure transducer, and data were
collected at 200 Hz. Systolic, diastolic, and mean blood pressures
together with heart rate were determined.
Experimental series. Blood pressure and heart rate was measured
for 0.5 h before mice were given a bolus of LPS (2 mg/kg iv, 055:B5
E. coli; Sigma) or vehicle. Blood pressure and heart rate were then
measured for 8 h. In one series, mice were followed for 20 h after the
LPS bolus. Experiments were performed in wild-type, COX-2/,
littermate COX-2/, and eNOS/ mice (C57BL/6J). In one series,
blood pressure and heart rate were measured for 0.5 h in wild-type
(C57BL/6) mice before they were given a bolus (0.1 mg/kg) of the
prostacyclin-2-receptor antagonist, BR5064 (a gift from Bayer Scher-
ing Pharma) followed by continuous infusion (0.005 g·kg1·h1) for
1 h. This was followed by a bolus of LPS (2 mg/kg). The specificity
of BR5064 was tested in other mice by first giving the mice a bolus
of beraprost (20 g/kg; Cayman Chemicals) leading to a decrease in
blood pressure within a few minutes. When blood pressure was stable
again, a bolus of BR5064 (0.1 mg/kg) was given followed by contin-
uous infusion (0.005 mg·kg1·h1) for 1 h. At the end of each
experiment, blood samples were drawn, and the aorta, liver, heart, and
kidneys were removed for further examination.
Measurements of eNOS, iNOS, Neuronal NOS, and COX-2,
1a- and 1-Adrenoceptor mRNA and eNOS Protein
Quatitative-PCR. Total RNA from kidney, liver, aorta, and heart
from control and LPS-treated animals was isolated by Trizol reagent
extraction according to the manufacturer’s instructions (Invitrogen)
and used as template for quantitative-PCR analysis as described by
Stubbe et al. (37). cDNA amplification was made using iQ SYBR
Green Supermix (Bio-Rad, Hercules, CA), and primer sequences are
shown in Table 1. A melting curve analysis confirmed specificity
postrun for each plate setup, and a standard curve was constructed by
plotting threshold cycle values against serial dilutions. Purified PCR
product was used to generate a standard curve.
Western blot analysis. Liver tissue was homogenized using a
sucrose/imidazole buffer modified from Jensen et al. (29). Next, 30 g
of protein was separated on a 4–15% Tris·HCl gel (Bio-Rad) and
transferred to a Immobilin-P polyvinylidene difluoride membrane
(Millipore). Membranes were blocked with 5% nonfat dry milk in
Tris-buffered saline Tween-20 (TBST) for 1 h followed by incubation
overnight at 4°C with primary antibody diluted 1:1,000 in 5% nonfat
dry milk in TBST. The primary antibody was anti-eNOS (ab5589;
Abcam, Cambridge, UK). The antigen-antibody complex was visual-
ized by horseradish peroxidise-conjugated secondary antibody (cat.
no. P0448, diluted 1:2,000; Dako) using the ECL plus Western
Blotting Detection System (GE Healthcare, Hillerod, Denmark). An-
tibody against -actin (1:2,000, Abcam) was used for loading control.
Isometric Force Measurements in Aorta Rings
Isometric force measurements in aorta rings were obtained in a
Halpern-Mulvany myograph (model 610 M; Danish Myo Technology,
Aarhus, Denmark). The mice were killed by a blow to the head
followed by decapitation. The thoracic aorta was rapidly excised and
placed in ice-cold physiological salt solution (PSS) as described (27).
This was followed by dissection and cutting the aorta into rings (1.5-
to 2-mm length) before incubation at 37°C with LPS (50 g/ml, E.
coli, 055:B5; Sigma) or vehicle for 18 h. Incubation media contained
DMEM (L-glutamine and HEPES; GIBCO) with 0.5% BSA (7.5%,
GIBCO), penicillin (100 /ml, Sigma), and streptomycin (100 g/ml,
Sigma). The rings were then suspended in the myograph at 37°C in
PSS with LPS, equilibrated with 5% CO2 in air (pH of 7.4). The rings
were normalized at resting tension, and the viability of the vascular
smooth muscle and endothelial cells were tested by adding phenyl-
ephrine (at 3 increasing concentrations: EC50, EC80, and EC100)
followed by acetylcholine (106 M). After normalization, the rings
were contracted with phenylephrine (EC50) for 1 h, and the experi-
ment was ended by adding acetylcholine (106 M).
Experimental series. Series 1: rings from wild-type mice (C57BL/
6J) incubated with LPS (50 g/ml) or vehicle; series 2: rings from
COX-2/ mice were incubated with LPS or vehicle and rings from
C57BL/6J were incubated with LPS and the selective COX-2 inhibitor
Table 1. Primer sequences
Product Sense, 5=-/-3= Antisense, 5=-/-3= Size, bp
eNOS GAG-AGC-GAG-CTG-GTG-TTT-G TGA-TGG-CTG-AAC-GAA-GAT-TG 187
iNOS ACT-GTG-TGC-CTG-GAG-GTT-CT TCT-CTG-CCT-ATC-CGT-CTC-GT 177
nNOS ACC-AGC-TCT-TCC-CTC-TAG-CC GCC-ATA-GAT-GAG-CTC-CGT-GT 158
COX-2 GGC-GTT-CAA-CTG-AGC-TGT GGA-ATT-CTC-ACT-GGC-TTA-TGT-AGA-G 241
Alpha-1a ACT-GAA-GGT-CCG-CTT-CTC-CT ACC-GGC-AGT-GAC-TCT-CAA-CT 180
Beta-1 ACG-CTC-ACC-AAC-CTC-TTC-AT AAG-TCC-AGA-GCT-CGC-AGA-AG 136
GAPDH TGA-TGG-CAT-GGA-CTG-TGG CAG-CAA-TGC-ATC-CTG-CAC 103
TBP CAG-CCT-TCC-ACC-TTA-TGC-TC TTG-CTG-CTG-CTG-TCT-TTG-TT 169
Tbcc GAC-TCC-TTC-CTG-AAC-CTC-TGG GGA-GGC-CAT-TCA-AAA-CTT-CA 62
eNOS, endothelial nitric oxide synthase; iNOS, inducible NOS; nNOS, neuronal NOS, COX-2, cyclooxygenase-2; GAPDH, liver and aorta; TBP, kidney;
Tbcc, heart.
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NS398 (10 mol/l) or LPS alone; series 3: rings from eNOS/ mice
incubated with LPS or vehicle, and rings from C57BL/6J were
incubated with LPS and the NOS inhibitor NG-nitro-L-arginine methyl
ester (L-NAME; 104 mol/l) and LPS or L-NAME alone; series 4: The
endothelium was removed in rings from C57BL/6J by 1% Triton
X-100 followed by incubation with LPS and L-NAME, LPS alone, or
vehicle; series 5: rings from wild-type mice (C57BL/6J) incubated
with LPS (50 g/ml) and the iNOS inhibitor 1400W (1 mol/l;
Cayman Chemicals) or LPS alone. LPS, L-NAME and 1400W were
dissolved in PSS.
Statistical Evaluation
Blood pressure data were integrated over 0.5 h before LPS and
thereafter for each hour. Changes in mean  SE of blood pressure
with time were compared by one-way ANOVA. If ANOVA was
significant, blood pressure values after LPS were compared with
blood pressure before LPS (control) by unpaired Student’s t-test with
Bonferroni correction. P  0.05 was considered significant. Between
groups (e.g., COX-2 genotypes) blood pressure decrease after LPS at
8 h (blood pressure) was compared by unpaired Student’s t-test.
Fig. 1. Effect of an intravenous LPS bolus (2 mg/kg,
n 	 11) or vehicle bolus (n 	 7) on mean arterial
blood pressure (MAP) and heart rate (HR) measured
by chronic indwelling catheters in conscious, freely
moving, wild-type (WT) mice. A: time course of
MAP in WT mice after an LPS or vehicle (control)
bolus. B: hourly averages of MAP in WT mice after
LPS bolus. Insert, right: average blood pressure
results from separate mice followed for 20 h. C: time
course of HR changes in WT mice after an LPS or
vehicle bolus. D: hourly averages of HR for 8 h in
WT mice after LPS bolus and for separate mice
followed for 20 h (insert, right). Columns show
means  SE. *Statistically significant difference
between basal values of MAP and HR before bolus
injection (0.5 h) and after LPS bolus at P  0.05.
Fig. 2. MAP and HR measured by indwelling
catheters in conscious cyclooxygenase-2
(COX-2)/ mice (n 	 7) and their WT
littermates (COX-2 /, n 	 7) after LPS (2
mg/kg) or vehicle (control). A: time course of
MAP in COX-2/ and COX-2/ mice after
LPS or vehicle bolus. B: hourly averages of
MAP in COX-2/ mice after an LPS bolus.
C: time course of changes in HR in COX-
2/ and COX-2/ mice after LPS or vehi-
cle bolus. D: hourly mean HR in COX-2/
mice after LPS bolus. Columns show means 
SE. *Statistically significant difference be-
tween basal MAP and HR before (0.5 h) and
after LPS bolus (P  0.05).
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Data testing vascular reactivity and expression levels of specific
mRNA and protein molecules were evaluated by unpaired Student’s
t-test. For each series, separate controls were always run in parallel.
P  0.05 was considered significant.
RESULTS
Effect of LPS on Arterial Blood Pressure and Heart Rate
in Wild-Type Mice
Blood pressure was followed for 8 h after LPS or vehicle
injection. Baseline MAP in catheterized, freely moving
C57BL/6 mice was 106.5  2.2 mmHg and heart rate was
613.1  11.7 beats/min. Injection of a vehicle bolus (iso-
tonic NaCl) had no acute effect on MAP or heart rate. After
LPS injection (2 mg/kg iv), blood pressure decreased sig-
nificantly after 2.5 h and stabilized at a level 
75 mmHg
after 6 h, which was an average decline of 32.2  3.8 mmHg
(Fig. 1, A and B; n 	 11). There was an almost synchronous
decrease in heart rate after LPS at 3 h, which stabilized at
a rate averaging 50% of control (
300 beats/min) at 6 h
(Fig. 1, C and D).
In separate mice, circulatory parameters were followed
for 20 h after LPS injection (n 	 6). These mice survived,
and blood pressure did not decrease further between 6 and
20 h. None of the tested mice died during the experiments
(Fig. 1, B and D, inserts, right). Analysis of tracks with
higher time resolution (average each 15 min) confirmed the
above; blood pressure declined significantly at 150 min with
no significant change in heart rate until 180 min, which then
also declined.
Effect of LPS on Arterial Blood Pressure and Heart Rate in
COX-2/ Mice and COX-2/
The resting MAP in C57BL/6J mice with targeted dele-
tion of COX-2 (COX-2/) averaged 112.3  3.3 mmHg
and in C57BL/6J wild-type littermates (COX-2/) 106.0 
3.3 mmHg was not significantly different (Fig. 2A). There
was no blood pressure difference between genders in COX-
2/ mice. Bolus injection of LPS resulted in a blood
pressure decrease that was significant after 2 h in COX-2/
and then stabilized 
80 mmHg (Fig. 2, A and B). The
change in blood pressure value after LPS was 26.2  3.6
mmHg for COX-2/ and 31.7  4.9 mmHg for COX-2/
and not significantly different between the two strains. Heart
rate was 622.2  20.6 beats/min in resting COX-2/ mice,
and an LPS bolus decreased it to 421.5  45.9 beats/min
(Fig. 2, C and D). The decrease in heart rate caused by LPS
Fig. 3. Blood pressure trace shows the effect
of the prostacyclin receptor agonist beraprost
(20 g/kg) on MAP in the absence (A, left)
and presence (B, right) of the prostacyclin
receptor antagonist BR5064 (0.1 g/kg bolus
and infusion 0.005 g·kg1·h1 for 1 h) in a
WT mouse. C: time course of MAP in WT
mice given an LPS bolus (n	 10) and an LPS
bolus with the prostacyclin receptor antago-
nist BR5064 (n 	 11). BR5064 was given at
0.5 h, and at 1.5 h LPS was added. D: hourly
MAP in BR5064-treated WT mice after LPS
bolus. E: time course of average HR in WT
mice after prostacyclin antagonist BR5064
with and without LPS bolus. F: hourly mean
HR in prostacyclin antagonist-treated mice
after LPS bolus. Columns show means  SE.
*Statistically significant difference between
basal MAP and HR and after LPS bolus at
P  0.05.
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was not significantly different between wild-type littermates
and COX-2/ (HR 244.1  55 and 202.7  56 beats/min,
respectively).
Effect of a Prostacyclin Receptor Antagonist on the
LPS-Induced Cardiovascular Functional Decline
Efficient blockade of prostacyclin was controlled by bolus
injection of the stable prostacyclin receptor agonist beraprost
(20 g/kg). In wild-type mice infused with vehicle, beraprost
injection yielded an acute, reversible decrease in blood pres-
sure (Fig. 3A). BR5064 (0.1 mg/kg bolus followed by 0.005
mg·kg1·h1 continuous infusion) abolished the effect of pros-
tacyclin agonist infusion (Fig. 3B). Administration of BR5064
had no significant effect on resting blood pressure or heart rate
(Fig. 3, C and E). BR5064 infusion to mice did not prevent a
significant decrease in blood pressure in response to an LPS
bolus (Fig. 3, C and D). Thus, after 4 h, blood pressure had
decreased significantly in LPS-treated, BR5064-infused
mice, and then stabilized at this level for the duration of the
experiment. The change in blood pressure (19.7  3.8
mmHg) was not significantly different from that observed in
vehicle-infused, LPS-treated mice. Heart rate decreased sig-
nificantly in response to LPS in BR5064-infused mice in a
way not significantly different from that in vehicle-infused
mice (Fig. 3, E and F).
Effect of LPS on Arterial Blood Pressure and Heart Rate
in eNOS/ Mice
C57BL/6J mice with targeted deletion of eNOS displayed a
significantly elevated resting blood pressure compared with
wild-type mice: MAP was 130.5  3.1 mmHg compared with
106.5  2.2 mmHg in control mice (Fig. 4A). Heart rate was
657.4  13 beats/min in eNOS/ mice (n 	 6) compared
with 613.1  12 beats/min in wild-type mice, which was not
significantly different. In eNOS/ mice, LPS treatment
yielded a significant decrease in MAP that was apparent 3 h
after the bolus injection (Fig. 4, A and B). Blood pressure then
stabilized at a level 
90 mmHg. The MAP decrease at 6 h
was 43.2  5 mmHg with no significant difference between
wild-type control mice and eNOS/ mice. In response to
LPS, heart rate displayed a significant decrease after 3 h and
stabilized 
300 beats/min (Fig. 4, C and D). The decrease in
heart rate after 6 h was 350.3 19 beats/min in wild-type mice
and was not significantly different between wild-type and
eNOS/ mice.
Effect of LPS on Contraction of Aortic Rings In Vitro
Segments of thoracic aorta from C57BL/6J mice were pre-
incubated with LPS and were subsequently suspended in a
myograph. The 1-adrenoceptor agonist phenylephrine was
used at EC50 (2  107 mol/l) for 60 min to examine the
ability of the rings to maintain tone. After incubation with LPS
(50 g/ml), the preparations exhibited a reproducible and
significant reduction of contractility in response to phenyleph-
rine (n 	 6) compared with control rings (n 	 5) (Fig. 5A). At
the end of each experiment, acetylcholine was added to test
endothelial function. Acetylcholine relaxed the control rings,
whereas acetylcholine induced a significant contraction in
LPS-treated rings (Fig. 5C). LPS-treated rings from COX-2/
mice (n 	 5) displayed a suppression of phenylephrine-in-
duced tone that was indistinguishable from that observed in
aorta harvested from wild-type mice (Fig. 5B). The COX-2
antagonist NS-398 had no significant effect on the vascular
reactivity of LPS-exposed rings (Fig. 5B, n 	 6). Aortic
segments from eNOS/ mice incubated with LPS also
showed a reduced contractility (n 	 5) to phenylephrine
stimulation not significantly different from that of arteries from
wild-type mice (Fig. 5B, n 	 6). Inhibition of NOS activity by
Fig. 4. MAP and HR measured by indwelling
catheters in conscious endothelial nitric oxide
synthase-disrupted (eNOS/) mice (n 	 6)
and WT mice (n 	 11) after an LPS bolus. A:
time course of MAP in eNOS/ and WT mice
after LPS (control trace is same as in Fig. 1A).
B: hourly MAP in eNOS/ mice before after
LPS bolus. C: time course of mean HR
in eNOS/ and WT mice after LPS bolus.
D: hourly mean HR decrease in eNOS/ mice
after LPS bolus. eNOS/ mice were com-
pared with WT control mice also shown in Fig.
1. Columns show means  SE. *Statistically
significant difference between basal MAP and
HR before (0.5 h) and after LPS bolus at P 
0.05.
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the addition of L-NAME or the iNOS inhibitor 1400W im-
proved phenylephrine-induced contractility in LPS-exposed
rings (each series n 	 6) to a level not significantly different
from control rings or from preparations incubated with
L-NAME only (Fig. 5B). Removal of the endothelium abol-
ished acetylcholine-mediated relaxations but did not affect
contractility determined as the response to EC50 of phenyleph-
rine (16.1  2.2 mN, n 	 5, Fig. 5B). Incubation of rings
without endothelium with LPS reduced contractility (4.1 1.0
mN, n 	 6) in response to phenylephrine to a similar extent as
that observed in preparations with endothelium (Fig. 5B).
Incubation of LPS-treated rings without endothelium with
L-NAME resulted in a significantly improved contraction to
phenylephrine (12.43  1.6 mN, n 	 6) compared with
LPS-treated aorta without endothelium not exposed to the NOS
inhibitor; there was no significant difference in contractility
compared with control rings without LPS and endothelium.
Effect of LPS on eNOS, iNOS, Neuronal NOS, COX-2,
and Adrenoceptor Expression in Mouse Organs
Total RNA from control and LPS-treated wild-type and
COX-2/ mouse liver, aorta, kidney, and heart was subjected
to quantitative RT-PCR analysis. In liver and kidney, systemic
LPS treatment yielded a significantly elevated level of iNOS
mRNA in wild-type and COX-2/ (Fig. 6A). COX-2 mRNA
was increased in liver (Fig. 6D). In aorta and left cardiac
ventricle there were no significant change in iNOS and COX-2
mRNA level (Fig. 6, A–D). The level of eNOS mRNA in liver,
aorta, and heart was significantly reduced in response to LPS
infusion in wild-type mice but not in COX-2/, whereas no
significant change was observed in the kidney (Fig. 6B).
Neuronal NOS (nNOS) mRNA was significantly downregu-
lated in kidney and liver in LPS-treated wild-type and
COX-2/ mice, with the same tendency in aorta and heart
(Fig. 6C). Total eNOS protein abundance in liver tissue was
not changed by LPS treatment in wild-type and in COX-
2/ mice as determined by Western blot analysis (Fig. 6F).
In contrast, iNOS protein level was significantly increased
by LPS in wild-type and COX-2/ mice compared with
control (Fig. 6E). The abundance of 1-adrenoceptor mRNA
in left ventricle was significantly decreased in wild-type and
COX-2/ in response to LPS (Fig. 6G). In aorta, there was
no significant change in mRNA abundance of the 1a-
adrenoceptor (Fig. 6H).
DISCUSSION
The present study shows that LPS-induced suppression of
heart rate and blood pressure in conscious, freely moving mice
is not attenuated by targeted deletion of COX-2 or eNOS, or by
pharmacologic inhibition of prostacyclin receptor. Results
from isolated aortic rings exposed to LPS corroborated the
interpretation that COX-2 and the endothelium/eNOS has no
major role in the depression of vascular reactivity caused by
LPS. By contrast, selective iNOS inhibition rescued vascular
contractility. LPS induced marked and opposite changes in the
expression of iNOS (up), nNOS (down), and eNOS (down)
mRNAs in vivo, which supports a crucial role of iNOS activity
for the decline in cardiovascular function, in line with previous
findings. Taken in conjunction, the present data show that
activity of COX-2 or eNOS and therefore a serial coupling
between them is less likely as cause for and therapeutic target
of cardiovascular collapse in LPS-mediated endotoxemia.
The present report provides cardiovascular data obtained at
the systemic level in conscious freely moving COX-2/ mice,
which constitute an attractive model to study the role of the
enzyme independently of nonselective actions of COX inhib-
itors and the variable pharmacokinetic conditions that prevail
Fig. 5. A: effect of the -adrenoceptor agonist phenylephrine (PE) on contrac-
tile force of mouse aortic rings preincubated with and without LPS (50 g/ml).
At termination of the experiment, acetylcholine (ACh; 1 M) was added to
elucidate endothelial function. Original recordings of 2 experiments performed
in parallel. B: mean contractile force in response to PE in aortic rings from
WT mice incubated with LPS (n 	 6) and without LPS (control, n 	 5 );
COX-2/ mice with LPS (n 	 5); WT mice with the COX-2 inhibitor
NS398 and LPS (n 	 6 ); eNOS/ mice with LPS (n 	 5 ); WT mice with
the NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME; n 	 6); WT
mice with the NOS inhibitor L-NAME and LPS (n 	 6); WT mice with the
inducible NOS (iNOS) inhibitor 1400W and LPS (N 	 6); endothelium-
denuded rings from WT mice (n 	 6); endothelium-denuded rings from WT
mice with LPS (n 	 6); endothelium-denuded rings from WT mice with
L-NAME and LPS (n 	 6). Columns show means  SE. *Statistically
significant difference between control and LPS; #significant difference be-
tween LPS alone and LPSinhibitor. C: mean contractile force in mouse aortic
rings preconstricted with PE before and after addition of ACh. In control rings,
ACh produced a significant relaxation, whereas a significant contraction was
seen in the LPS-preincubated rings. Columns show means  SE. *Statistically
significant difference between control and ACh.
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during sepsis (18). The present model of LPS-induced endo-
toxemic shock resulted in hypotension and reduced heart rate
with onset after 2 to 3 h that lasted for at least 20 h while mice
survived. The “mild” LPS dosing regimen (2 mg/kg iv) is
different from a study designed to examine survival, where
COX-2/ mice were significantly protected from death com-
pared with COX-2/ in response to LPS (3 daily injections of
40 mg/kg ip or 100 mg/kg ip once) (19). The present obser-
vations suggest that the better survival in COX-2/ mice and
in mice given COX-2-selective blockers (4, 34) is less likely to
be caused by an improved cardiovascular function. Of note,
two selective COX-2 inhibitors and the glucocorticoid-receptor
agonist dexamethasone showed equal ability to suppress the
excretion of prostacyclin metabolite 6-keto-PGF1 in rats after
LPS, but only dexamethasone improved arterial pressure and
attenuated the rise in plasma levels of nitrite and nitrate caused
by LPS (30). This finding supports a modest role of COX-2
activity for blood pressure decline compared with NOS activ-
ity. Efficient in vivo blockade of prostacyclin receptors was
obtained, but the prostacyclin antagonist did not attenuate the
LPS-mediated suppression of MAP and heart rate. COX-2
being the dominant source for systemic prostacyclin (31), the
present finding is in accord with the lack of effect of COX-2 on
systemic hemodynamics (13). In rats subjected to endotoxemic
shock, both a COX-2 inhibitor, rofecoxib, and a prostacyclin
antagonist, CAY-10441, attenuated the LPS-mediated decrease
in blood pressure (25, 26). These experiments were performed
during isoflurane anesthesia and used 5 times the present dose
Fig. 6. mRNA levels for iNOS (A), eNOS (B), neuronal
NOS (nNOS; C), and COX-2 (D) in kidney, liver, aorta,
and heart as measured by quantitative RT-PCR (qRT-
PCR) in WT mouse tissues (wt) and tissue from COX-
2/ treated with LPS () and controls (). Tissues
were harvested from mice 8 h after the LPS bolus.
mRNA levels are shown relative to GAPDH (liver and
aorta), TBP (kidney), and Tbcc (heart) and expressed as
fold change compared with control. Columns show
means  SE. *Statistically significant difference be-
tween () and () (P  0.05; unpaired t-test). Protein
level of total eNOS (F) and iNOS (E) in liver tissue from
vehichle-treated and LPS-treated WT mice and LPS-
treated COX-2/ mice (n 	 4 for each condition).
mRNA levels for 1-adrenoceptor in heart (G) and 1-
adrenoceptor in aorta (H) measured by qRT-PCR in WT
mouse tissues and tissue from COX-2/ treated with
LPS () and controls (). Tissues were harvested from
mice 8 h after the LPS bolus. mRNA levels are shown
relative to GAPDH (aorta) and Tbcc (heart) and are
expressed as fold change compared with control. Col-
umns show means  SE. *Statistically significant differ-
ence between () and () (P  0.05; unpaired t-test).
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of LPS (10 mg/kg) given intravenously. Baseline blood pres-
sure was 80–90 mmHg and during LPS at or below 50 mmHg.
These different experimental conditions may explain the dis-
crepancies with the present findings obtained in conscious
mice, although species differences may also be involved. Rats
display a hyperdynamic circulatory response to LPS with
increased heart rate and cardiac output (almost doubled), while
blood pressure drops and systemic vascular resistance is mark-
edly lowered (26). This suggests a sequence where the primary
event is either vasodilatation with a compensatory increase in
heart rate or a directly mediated inflammatory tachycardia
inducing a reflex decrease in peripheral resistance. In mice,
however, the basal heart rate approximated 600 beats/min, and
in no case was an increase in response to LPS recorded. A
decline in blood pressure was noted first, and within 30 min
this was followed by a decline in heart rate with no compen-
satory tachycardia. The almost syncronous drop in blood pres-
sure and heart rate suggest inadequate responsiveness in or
effect of the sympathetic nervous system and/or suppressed
inotropic state of the myocardium. Cytokines downregulate
-adrenoceptors in various organs during endotoxemia in rats
(11), whereas the 3-adrenoceptor is upregulated in human
myocardium from septic patients (32). Our results show a
decrease of 1-adrenoceptor expression to 10% of control level
in left ventricular myocardium, while aortic 1a-adrenoceptor
expression showed no alteration. If present at the level of
functional receptors, this myocardial downregulation could
cause a lower sensitivity towards sympathetic stimulation.
The lack of contribution of COX-2-derived prostanoids in
the blood pressure response to LPS is in accord with modest
and restricted upregulation of COX-2 mRNA in the liver. The
data agree with previous data from mice where COX-2 changes
transiently in vivo (20). In accord with earlier reports (28, 35),
MAP was increased by 
30 mmHg in eNOS/ mice. A
significant role has been attributed to eNOS in endotoxemic
(17, 38) and anaphylactic (14) blood pressure decrease, and the
COX products PGE2 and prostacyclin can activate eNOS (22,
27, 33). The present data indicate that both in conscious mice
and in isolated vascular rings, eNOS is downregulated and
does not contribute to cardiovascular suppression. eNOS pro-
tein abundance is also decreased in endothelial cells in a model
of cecal ligation and puncture in rats (39). Thus LPS modulates
the expression of the three NOS isoforms differently since both
eNOS and nNOS were suppressed and iNOS stimulated. nNOS
is expressed in vascular smooth muscle cells (10) and endo-
thelium (5). It contributes to endothelium-dependent relaxation
in mouse aorta (12), and in accordance with our findings,
nNOS is also downregulated in cardiac myocytes from rats in
a model of endotoxic shock (16). The suppression of vascular
eNOS abundance is in accord with disappearance of the relax-
ation to acetylcholine. Actually, and surprisingly, in isolated
preparations incubated with LPS, acetylcholine caused an in-
crease in tension rather than a relaxation. This probably reflects
the induction of endothelium-dependent contractions, as has
been observed with another cytokine in the aorta of the rat (9).
The present data rather support that iNOS is the major
source of NO in response to LPS, since iNOS mRNA was
enhanced several times in liver and kidney, while in vitro,
L-NAME, as well as selective iNOS inhibition, normalized
LPS-suppressed vessel reactivity. This is in accord with obser-
vations in LPS-challenged awake mice, where systemic NO
production depended solely on iNOS and where eNOS-derived
NO was reduced (23). This finding has been reproduced also in
vitro, where iNOS activity suppressed eNOS expression and
abolished acetylcholine-mediated dilatation in aortic rings of
the mouse (15). The present in vitro observations suggest that
LPS-stimulated iNOS activity in the arterial media layer is
sufficient to suppress vascular reactivity. Although endothelial
cells also may respond to LPS by upregulation of COX-2 (1)
and iNOS, this appears not to be necessary for suppression of
vascular reactivity. The role of the endothelium in sepsis is,
although, not completely clear.
Perspectives and Significance
In summary, the present study shows that a nonlethal, acute,
inflammatory challenge by infusion of gram-negative bacterial
wall-derived LPS to conscious unrestrained mice reduces si-
multaneously heart rate and MAP in vivo and vascular reac-
tivity in vitro, independently of COX-2, prostacyclin receptors,
and endothelium/eNOS activity. Thus, at least in the mouse, a
serial coupling between COX-2 and eNOS activities is unlikely
to account for acute cardiovascular depression during endotox-
emia, while iNOS appears to be of major significance.
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